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ABSTRACT
Objective: To present the pregnancy results and
interim birth results of a pragmatic randomised
controlled trial comparing routine iron prophylaxis with
screening and treatment for anaemia during pregnancy
in a setting of endemic malaria and HIV.
Design: A pragmatic randomised controlled trial.
Setting: Two health centres (1° de Maio and
Machava) in Maputo, Mozambique, a setting of
endemic malaria and high prevalence of HIV.
Participants: Pregnant women (≥18-year-olds;
non-high-risk pregnancy, n=4326) attending prenatal
care consultation at the two health centres were
recruited to the trial.
Interventions: The women were randomly allocated
to either Routine iron (n=2184; 60 mg ferrous sulfate
plus 400 μg of folic acid daily throughout pregnancy)
or Selective iron (n=2142; screening and treatment for
anaemia and daily intake of 1 mg of folic acid).
Outcome measures: The primary outcomes were
preterm delivery (delivery <37 weeks of gestation) and
low birth weight (<2500 g). The secondary outcomes
were symptoms suggestive of malaria and self-reported
malaria during pregnancy; birth length; caesarean
section; maternal and child health status after delivery.
Results: The number of follow-up visits was similar in
the two groups. Between the first and fifth visits, the
two groups were similar regarding the occurrence of
fever, headache, cold/chills, nausea/vomiting and body
aches. There was a suggestion of increased incidence
of self-reported malaria during pregnancy (OR 1.37,
95% CI 0.98 to1.92) in the Routine iron group. Birth
data were available for 1109 (51%) in the Routine iron
group and for 1149 (54%) in the Selective iron group.
The birth outcomes were relatively similar in the two
groups. However, there was a suggestion (statistically
non-significant) of poorer outcomes in the Routine iron
group with regard to long hospital stay after birth
(relative risk (RR) 1.43, 95% CI 0.97 to 1.26; risk
difference (RD) 0.02, 95% CI −0.00 to 0.03) and
unavailability of delivery data (RR 1.06, 95% CI 1.00 to
1.13; RD 0.03, 95% CI −0.01 to 0.07).
Conclusions: These interim results suggest that
routine iron prophylaxis during pregnancy did not
confer advantage over screening and treatment for
anaemia regarding maternal and child health. Complete
data on birth outcomes are being collected for firmer
conclusions.
ARTICLE SUMMARY
Article focus
▪ The benefits of iron prophylaxis during preg-
nancy on maternal and child health (MCH) in
developing country settings with endemic
malaria and high prevalence of HIV is unclear.
▪ Iron has been linked to increased risk of infections.
▪ Among children less than 3 years, there are indi-
cations of harm of universal iron prophylaxis.
Key messages
▪ Routine iron prophylaxis during pregnancy did not
suggest better maternal and child health (MCH)
outcomes than screening and treatment for
anaemia in a setting of endemic malaria and HIV.
Strengths and limitations of this study
▪ So far, this represents the largest trial investigat-
ing the benefits of prophylactic iron during preg-
nancy on MCH in malaria-endemic settings.
▪ The compliance of the study nurses with the trial
protocol and that of the women with regard to
uptake of the iron and folic acid tablets was
good, as was the follow-up during pregnancy.
▪ The collection of delivery data was challenging,
resulting in up to an estimated 40% of missing
birth data, which are now been traced using
various methods.
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Trial registration: The trial is registered at ClinicalTrials.gov,
number NCT00488579 ( June 2007). The first women were
randomised to the trial proper April 2007–March 2008. The pilot was
November 2006–March 2008. The 3-month lag was due to technical
difficulties in completing trial registration.
INTRODUCTION
Despite the widespread recommendation of routine iron
prophylaxis during pregnancy, its beneﬁts and risks for
the mother and child, beyond the reduction of the risk
of anaemia, remain unclear, particularly in low-income
settings. Reviews of randomised controlled trials (RTCs)
performed for the Cochrane Collaboration and the
WHO have failed to conclude on the effects of routine
iron prophylaxis during pregnancy on pregnancy and
birth outcomes.1 2 There is some evidence that high
haemoglobin concentration in late pregnancy may be
associated with adverse effects on pregnancy.3 4 Based
on the evidence from non-pregnant populations, it has
been suggested that iron may advance the rate of infec-
tions.5–7 The host requires iron for biochemical func-
tioning, but iron may as well promote the replication of
infectious agents.6 For developing country settings which
are still plagued by infectious diseases, such as malaria
and HIV, the possible association between iron and
infections raises serious public health concerns.8 9
Previous trials conducted in malarial developing
country settings that have evaluated the effects of iron
supplementation during pregnancy on maternal and
child outcomes have been hampered by small samples,
large dropouts and several outcome-related exclu-
sions.10–14 The ﬁndings from the trials were conﬂicting
on the role of prophylactic iron supplementation on
birth weight, prematurity, perinatal mortality, incidence
of malaria and other pregnancy and birth outcomes.
Consequently, the evidence they provide is insufﬁcient
in addressing the question of the advantages and disad-
vantages of prenatal prophylactic iron. The results of
studies from non-malarial areas,15–21 although of better
quality, may not be relevant due to different settings.15–
21 Although the results were also conﬂicting in a
number of outcomes, the main ﬁndings included
slightly longer birth length, longer gestational age and
reduced risk of preterm delivery, intrapartum haemor-
rhage, low birth weight and infant and child mortality in
the iron–folic acid group.22
This limited evidence and the importance of iron
prophylaxis in prenatal programmes call for further
investigation on the beneﬁts of prenatal iron supplemen-
tation in areas of endemic malaria and with a high
prevalence of HIV. Using a pragmatic RCT, we investi-
gated the effects of routine iron prophylaxis throughout
pregnancy compared with screening and treatment for
anaemia on maternal and child health (MCH) in
Maputo, Mozambique. The present paper presents the
pregnancy results and interim birth results. About 40%
of births were missed by the original data collection
method;22 the missing birth data are currently being
retrieved with various complementary methods. The
completed birth results will be presented later.
MATERIALS AND METHODS
Study design and population
The details of the PROFEG trial have been described
elsewhere22 and only the main features are given here.
The trial was a pragmatic RCT to compare two iron
administration policies (routine iron prophylaxis vs
screening and treatment for anaemia during pregnancy)
on MCH in Maputo, Mozambique. The trial was carried
out in two health centres, 1o de Maio in Maputo City,
the capital (November 2006—October 2008), and
Machava 2 in Maputo Province ( June 2007—October
2008), Mozambique. The completion of collection of
birth data continued until 2012. The health centre of
Machava 2 in Maputo province is close to Maputo city.
The population is urban and semiurban, and malaria is
endemic in both areas. A seasonal increase of malaria is
usually observed towards the end of the rainy season
(February–April).23
In the study area, all woman were eligible to attend pre-
natal care. The usual care recommendations at the time
of the trial included daily prophylactic iron–folate supple-
mentation (60 mg+400 μg) throughout pregnancy; one
dose of mebendazol 500 mg for intestinal parasite; three
doses of sulfadoxine pyrimethamine for malaria prophy-
laxis (started around 20 weeks gestation, or when quick-
ening occurs or when the fetal heart is heard);
haemoglobin measurement (Lovibond is routinely used)
and syphilis screening at the ﬁrst prenatal visit and three
doses of tetanus vaccine (at the ﬁfth and seventh months
and at delivery). If malaria was suspected during prenatal
consultations, it was diagnosed by laboratory tests and
clinical signs. In most health centres, including our study
centres, HIV testing was offered.22 Antiretroviral (ARV)
drugs were provided by various international organisa-
tions, but we do not have information of how many
women received treatment during pregnancy. The rec-
ommendation was to give ARV (Nevirapine) at delivery to
prevent mother–child transmission.
Recruitment of study participants
Pregnant women attending their ﬁrst prenatal visit were
the target group. During the routine early morning
health education sessions, all women who came for their
ﬁrst prenatal visit were given general information about
the study. Recruitment into the study occurred during
individual consultations and was carried out by study
nurses who were employed and trained by the project. In
the 1° de Maio health centre, the women visited the study
nurses after their routine prenatal care consultations with
the MCH nurses. In Machava, the study nurse and the
routine MCH nurse saw the women in the same room.
The study nurses checked for the women’s eligibility to
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participate in the study. The exclusion criteria were:
women with high obstetric risk and those aged less than
18 years. If eligible, the nurses asked the women to join
the study. Oral and written informed consent was
obtained. Three types of women were missed from the
study: women whom MCH nurses sent back home
because of too early pregnancy, women who did not go to
the study nurse and women who refused the study.
Randomisation
The women were randomised into either the Routine
iron group (ie, routine iron prophylaxis from the ﬁrst to
the last prenatal visit) or the Selective iron group (ie,
regular screening for haemoglobin level and treatment
for anaemia). Researcher (OA) used the STATA statis-
tical software (StataCorp LP, Texas, USA) to generate
sequential random numbers separately for the two
centres, and the women were assigned to either of the
groups with a probability of 50%. The codes for the
groups were put into sealed and numbered opaque
envelopes; the number was the woman’s study number
and was repeated in the documents in the envelope.
The envelope contained a study identiﬁcation card
(yellow for the Routine iron group and pink for the
Selective iron group, 10×20 cm) and the informed
consent form.
Sample size
We did not have up-to-date reliable baseline data of
pregnant women’s and newborns’ health in Maputo or
of the effects of iron on pregnancy and birth outcomes.
Thus, we used different estimates of the baseline values
for preterm delivery, low birth weight, clinical malaria
and perinatal mortality to calculate the sample size, with
power (85% and 90%), signiﬁcance level of 5% and the
size of the difference to be detected (20% and 30%).
Based on these calculations and the expected feasibility,
we decided on a sample size of 2000 women in each
group to be enough to measure clinically meaningful
effects. The STATA statistical software was used to esti-
mate the sample size. A table showing the various base-
line assumptions used for power calculation and in
estimating the sample size for the study is included as
online supplementary appendix 1.
Interventions
On each prenatal visit, women in the Routine iron
group received 30 tablets (supply of 1 month) of 60 mg
ferrous sulfate plus 400 μg of folic acid per day com-
bined in one tablet. In the Selective iron group,
women’s haemoglobin levels were measured at each visit
by the study nurses using a rapid haemoglobin measure,
HemoCue Hb 201+, (Hemocue AB, Ängelholm,
Sweden). If the haemoglobin was 9 g/dl or more, they
received 30 tablets of 1 mg of folic acid per day. If their
haemoglobin was below the cut-off of <9 g/dl haemoglo-
bin, they received a monthly double dose of iron (60 mg
+60 mg) for the treatment of anaemia. Folic acid 1 mg
tablets were used because at the time of the trial pure
folic acid was not licensed in Mozambique in 400 μg
tablets. The tablets were given in a plastic bag having
the drug’s name and dosage on it.
Data collection and follow-up
Data were collected on standard study data forms by
three methods: (1) study nurses abstracted prenatal data
from mothers’ maternity cards, (2) study nurses asked
women additional questions at the time of the prenatal
visits and (3) study nurses or researchers collected birth
data afterwards from hospital birth records. Delivery
nurses were informed of the study and asked to put the
delivery cards into a separate study box. The study
women were to be identiﬁed by the colour of the identi-
ﬁcation card stapled to their maternity card. However,
this did not succeed very well. By excluding estimated
late miscarriages (5%), early stillbirths (3%) and home
births (10%), we should have received delivery data for
3547 women (82%) of the 4326 women who partici-
pated in the trial. We received birth data for only 2258
(64% of the estimated 3547) women.
Outcome measures
The primary outcomes were preterm delivery (delivery
<37 weeks of gestation and low birth weight (<2500 g);
data on weight came from the birth records; for gesta-
tion weeks, various routine data sources were used (see
below). Originally, we had malaria activation as a
primary outcome, but the pilot showed that it was not
feasible. Secondary outcomes were perinatal mortality
(as available from our data collection forms; unlikely to
cover early stillbirths or neonatal deaths occurring at
home); complications during pregnancy and labour;
symptoms suggestive of malaria (fever, headache, cold/
chills, nausea/vomiting and body aches) and self-
reported malaria during pregnancy (the woman was
asked for diagnosed malaria since her last visit).
Gestational weeks
In the prenatal visits, routine MCH nurses determined
gestational weeks in various ways, even though all ways
were not systematically noted down. In the ﬁrst prenatal
visits, the date of the last menstrual period, uterine
fundal height, assumed date of delivery and length of
gestation (best estimate) were noted. The study nurses
abstracted all this information and the best estimate was
used in this paper. In birth records, the last menstrual
period, date of fertilisation, assumed date of fertilisation
and length of gestation were to be given by the delivery
nurses. However, these data were very poorly ﬁlled and
only 681 (30%) of the women with delivery data had
their gestational weeks recorded at birth. Thus, the ges-
tational weeks for women without that information were
estimated from dates using the following algorithm: ges-
tational weeks at ﬁrst visit in days+days between the ﬁrst
visit and delivery; the days were then transformed into
weeks. For some women (n=196), the date of delivery
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was not available. In these cases, the date of discharge
from the hospital after delivery (minus the length of stay
at the hospital; n=22) or the date of admission to the
hospital (n=60 women who did not have the date of dis-
charge) was used.
Adherence
The women were instructed and encouraged at each visit
to take the tablets they were given. Women allocated to
the Routine iron group could refuse to take the iron
tablets; in that case, they were classiﬁed as non-compliant
with the intervention. Women who belonged in the
Selective iron group and who wanted iron (even if their
haemoglobin level was not below the cut-off level) were
given iron; they were classiﬁed as non-compliant with the
intervention. The following questions were asked on each
visit: ‘Was hemoglobin measured?’; ‘Was iron/folic acid
given to the woman?’; ‘Number of iron/folic acid tablets
given?’; ‘Did the woman take the tablets during the past
week?’ At each subsequent visit, almost all of the Selective
iron women (98%) were measured for haemoglobin
using the recommended HemoCue method and the
same proportion of women in the Routine iron group
were given iron tablets at each subsequent visit.
Statistical analysis
All analyses were performed on an intention-to-treat
basis. Twin pregnancies (n=48 pairs) were included in
the analysis because their numbers were similar in the
two groups and their exclusion did not alter the results.
For pregnancy outcomes, all women (n=4326) were
included, whereas for birth outcomes, women with birth
data (n=2258) were included. Differences in health indi-
cators (fever, headache, cold/chills, nausea/vomiting,
body aches, malaria) between the two iron groups at
each subsequent visit (up to the ﬁfth visit) during
pregnancy were analysed by using binomial generalised
estimating equations (GEE) with an exchangeable cor-
relation structure. GEE takes into account the within
person correlation in the setting of repeated measures.
Differences in continuously distributed birth outcomes
(birth weight, duration of gestation, length of hospital
stay) were analysed by using the two sample Student
t tests. Categorical outcomes were analysed by using
Pearson’sχ2 test or Fisher’s exact test (in the case of cells
with less than ﬁve cases). To estimate the risk ratios of
the effect of iron, the binary birth outcomes (low birth
weight (<2500 g), preterm birth (<37 weeks), caesarean
section delivery, child and maternal ill-health or death at
Figure 1 PROFEG Trial flow
diagram. 1ARO, high-risk
pregnancy; 2GA, gestational age
in weeks; 3After recruitment, %
were calculated from recruited,
n=4326.
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Table 1 Characteristics of women at recruitment by availability of delivery data and group allocation, proportions %
(numbers)
Delivery data (n=2258) No delivery data (n=2068)
Characteristics
Selective iron (1149)
% (n)
Routine iron (1109)
% (n)
Selective iron (993)
% (n)
Routine iron (1075)
% (n)
Maternal age, mean (SD) years 24.6 (5.4) 24.7 (5.3) 25.0 (5.6) 24.6 (5.6)
Maternal age (years) (categorised)
<20 17.5 (201) 16.5 (183) 15.7 (156) 19.3 (207)
20–24 41.1 (472) 39.9 (443) 39.0 (387) 37.1 (399)
25–29 23.1 (265) 23.3 (258) 23.9 (237) 23.4 (252)
30–34 11.3 (130) 13.8 (153) 12.9 (128) 13.3 (143)
≥35 6.3 (72) 5.6 (62) 7.4 (74) 6.5 (70)
Missing 0.8 (9) 0.9 (10) 1.1 (11) 0.4 (4)
Haemoglobin by HemoCue (g/dl),
mean (SD)
9.6 (1.7) 9.6 (1.7)
Haemoglobin by HemoCue (g/dl), n (%)
<7.0 6.9 (79) 6.2 (62)
7.0–8.90 24.6 (283) 25.4 (252)
9.0–9.90 23.5 (270) 24.4 (242)
10.0–10.90 21.9 (252) 21.1 (210)
11.0–11.90 14.1 (162) 13.7 (136)
≥ 12.0 7.9 (91) 8.4 (83)
Not measured 1.0 (12) 0.8 (8)
Previous abortions
No 87.6 (1007) 86.8 (963) 86.0 (854) 85.4 (918)
Yes 12.1 (139) 12.8 (142) 13.6 (135) 14.5 (156)
Missing 0.3 (3) 0.4 (4) 0.4 (4) 0.1 (1)
Gestational age, mean (SD)
weeks
21.6 (5.9) 21.7 (5.6) 21.0 (5.9) 21.3 (5.8)
Gestational age (categorised)
<16 19.2 (221) 16.4 (182) 21.5 (213) 20.1 (216)
17–20 21.8 (250) 24.2 (268) 22.5 (223) 21.7 (233)
21–26 34.3 (394) 32.6 (361) 31.3 (311) 33.7 (362)
>27 19.7 (226) 19.7 (219) 17.5 (174) 18.2 (196)
No information 58 (5.0) 7.1 (79) 7.3 (72) 6.3 (68)
Previous stillbirths
No 91.5 (1052) 92.3 (1024) 91.6 (910) 91.0 (978)
Yes 8.2 (94) 7.2 (80) 7.9 (78) 8.9 (96)
Missing 0.3 (3) 0.5 (5) 0.5 (5) 0.1 (1)
Previous deliveries
None 29.7 (341) 30.3 (336) 29.2 (290) 33.8 (363)
One 31.9 (367) 31.7 (352) 30.6 (304) 28.5 (306)
Two 19.2 (221) 17.8 (197) 17.9 (178) 18.6 (200)
Three or more 18.8 (216) 19.8 (220) 22.0 (218) 19.0 (205)
Missing 0.4 (4) 0.4 (4) 0.3 (3) 0.1 (1)
HIV status
Negative 81.2 (934) 81.8 (907) 76.7 (762) 79.0 (849)
Positive 18.8 (215) 18.2 (202) 23.3 (231) 21.0 (226)
Twin pregnancy
No 98.7 (1134) 98.6 (1093) 99.2 (985) 99.2 (1066)
Yes 1.3 (15) 1.4 (16) 0.8 (8) 0.8 (9)
Symptoms during current pregnancy before first prenatal visit
Fever
Yes 22.9 (264) 24.4 (271) 28.8 (286) 23.8 (256)
Headache
Yes 41.5 (477) 43.5 (482) 44.3 (440) 43.0 (462)
Cold/chills
Yes 18.0 (207) 18.4 (204) 20.6 (205) 18.8 (202)
Vomit/nausea
Continued
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birth, negative fetal heart beat, delivery in a reference
health centre, long hospital stay after birth (≥ 2 days)
and unavailability of delivery data) were analysed by
generalised linear models. The result estimates are
presented with 95% CI. Statistical signiﬁcance was
set at p<0.05. STATA V.11 statistical software was used
for the analyses.
RESULTS
Of the 4326 women recruited to the trial, 2184 were ran-
domly allocated to the Routine iron group and 2142 to
the Selective iron group (ﬁgure 1). The total number of
prenatal visits varied, but the maximum number of visits
was seven. The number of follow-up visits was similar in
the two groups (ﬁgure 1). About 40% of the delivery
data were missed when using the original data collection
method and the interim birth data were available for
1109 (51%) in the Routine iron group and for 1149
(54% of women) in the Selective iron group.
Table 1 compares maternal background characteristics
between groups by the availability of birth data. Mean
haemoglobin for the Selective group was similar between
those with and without delivery data. The occurrence of
symptoms suggestive of malaria (fever, headache, cold/
chills, nausea/vomiting and body aches) and self-
reported malaria during the current pregnancy prior to
the ﬁrst prenatal visit was similar between the Routine
and Selective iron groups. The women in the two groups
with and without birth data were comparable.
Between the ﬁrst and ﬁfth visits, the two groups were
similar regarding the occurrence of fever, headache,
cold/chills, nausea/vomiting and body aches (table 2).
There was a suggestion of increased incidence of self-
reported malaria during pregnancy (OR 1.37, 95% CI
0.98 to 1.92) in the Routine iron group (table 2).
Table 2 presents the data for the second and third
follow-up visits, but this was the case also in subsequent
visits (data not shown).
Table 3 presents the distribution of birth data by inter-
vention group and table 4 gives the estimates of the
effect sizes on the birth outcomes. The birth outcomes
were similar in the two groups. However, there was a sug-
gestion (statistically non-signiﬁcant) that the Routine
iron group had worse outcomes in regard to babies with
a negative heartbeat at admission and longer mother’s
hospital stay after birth (table 3). The effect of iron on
the primary outcomes was similar in the two groups.
Table 1 Continued
Delivery data (n=2258) No delivery data (n=2068)
Characteristics
Selective iron (1149)
% (n)
Routine iron (1109)
% (n)
Selective iron (993)
% (n)
Routine iron (1075)
% (n)
Yes 27.5 (316) 26.9 (298) 29.8 (296) 28.6 (307)
Body aches
Yes 21.8 (251) 21.3 (237) 23.8 (236) 23.3 (251)
Self-reported malaria
Yes 5.7 (66) 6.0 (67) 5.9 (59) 6.3 (68)
Had malaria test
Yes 7.0 (80) 7.1 (79) 8.0 (79) 7.9 (85)
Table 2 Proportions (%) of women (numbers) with outcomes suggesting malaria during pregnancy, and OR and 95% CIs
for group effect, n=4326
Outcomes
Second visit* % (n) Third visit† % (n)
Between the first and fifth visit‡
OR (95% CI)
Selective
iron n=1455
Routine iron
n=1494
Selective
iron n=1040
Routine iron
n=1106
Selective
iron Routine iron p Value
Fever 11.5 (168) 10.0 (150) 11.3 (117) 12.1 (134) 1.00 0.95 (0.81 to 1.11) 0.523
Headache 24.9 (363) 24.3 (363) 24.9 (259) 25.1 (278) 1.00 0.98 (0.87 to 1.10) 0.738
Cold/chills 8.2 (120) 7.0 (104) 6.7 (70) 7.8 (86) 1.00 0.92 (0.76 to 1.11) 0.361
Vomit/nausea 9.1 (133) 10.2 (153) 8.5 (88) 9.6 (109) 1.00 1.09 (0.92 to 1.31) 0.323
Body aches 10.1 (147) 9.2 (138) 10.9 (113) 9.8 (108) 1.00 0.89 (0.75 to 1.06) 0.180
Self-reported
malaria
2.4 (35) 3.0 (45) 1.5 (16) 2.2 (24) 1.00 1.37 (0.98 to 1.92) 0.068
*Between the first and second visit.
†Between the second and third visit.
‡The effect estimates calculated by binomial generalised estimating equations (with exchangeable correlation structure) to account for the
repeated measures of the outcomes.
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The groups were also relatively similar concerning most
other outcomes. However, there was a suggestion of
more babies with negative fetal heartbeat at admission,
longer mother’s hospital stay after birth and
unavailability of delivery data in the Routine iron group
(table 4). By excluding births by caesarean section, the
estimates for longer mother’s hospital stay remained the
same (data not shown).
Table 3 Birth outcomes by group allocation, percentages, % (numbers) of women or babies or means (SD)
Outcomes Selective iron (n=1149) Routine iron (n=1109) p Value*
Birth weight, mean (SD) grams 2996.3 (508.4) 2989.4 (514.9) 0.752
Birth weight (g), % (n) 0.443
<2500 11.8 (136) 12.8 (142)
2500–2999 30.6 (351) 31.1 (345)
3000–3499 40.5 (465) 37.8 (419)
3500–3999 12.7 (146) 13.8 (153)
≥4000 3.0 (34) 2.1 (23)
No information 1.5 (17) 2.4 (27)
Duration of gestation, mean (SD) weeks 38.3 (4.2) 38.4 (4.0) 0.689
Duration of gestation, % (n) 0.056
<37 weeks 28.8 (331) 27.0 (299)
≥37 weeks 67.2 (772) 66.9 (742)
No information 4.0 (46) 6.1 (68)
Mode of delivery, % (n) 0.235
Normal 87.6 (1007) 89.4 (991)
Caesarean section 1.3 (15) 2.0 (22)
No information 11.1 (127) 8.7 (96)
Child health status at birth, % (n) 0.685
Well 94.0 (1080) 92.1 (1022)
Ill 0.7 (8) 1.0 (11)
Dead 1.8 (21) 2.0 (22)
No information 3.5 (40) 5.0 (55)
Still birth, % (n) 0.558
No 81.2 (933) 79.7 (884)
Yes 2.5 (29) 2.9 (32)
No information 16.3 (187) 17.4 (193)
Fetal heart beat at admission, % (n) 0.085
Negative 1.6 (18) 2.6 (29)
Positive 85.6 (984) 85.2 (945)
No information 12.8 (147) 12.2 (135)
Mother’s health status at birth, % (n) 0.895
Well 95.6 (1098) 94.9 (1052)
Ill 0.4 (4) 0.4 (4)
Dead 0.1 (1) 0.2 (2)
No information 4.0 (46) 4.6 (51)
Length of hospital stay, mean (SD) days 1.33 (1.21) 1.63 (1.30) 0.075
Length of hospital stay after birth, % (n) 0.103
≤1 day 65.1 (748) 60.7 (673)
2 days 23.5 (270) 24.2 (268)
≥3 days 4.0 (46) 5.6 (62)
No information 7.4 (85) 9.6 (106)
Place of delivery, % (n) 0.652
1o de Maio (health centre) 44.4 (510) 42.6 (472)
Machava (health centre) 35.1 (403) 38.2 (424)
Jose Macamo (hospital) 3.7 (43) 3.6 (40)
Mavalane (hospital) 14.3 (164) 12.8 (142)
Central hospital 0.3 (3) 0.3 (3)
At home 1.1 (13) 1.3 (14)
On the way to hospital 0.0 (0) 0.2 (2)
No information 1.1 (13) 1.1 (12)
*Based on t test for continuous outcomes, Pearson’s χ2 test or Fisher’s exact test for categorical outcomes. Subjects with no information were
not included in the tests.
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DISCUSSION
The results from this trial indicate that routine iron
prophylaxis during pregnancy was not advantageous over
the policy of screening and treatment for anaemia with
regard to pregnancy and birth outcomes. If anything,
screening and treatment for anaemia appeared to be
better. Among all the trial women, there was a suggestion
of an increased risk of self-reported malaria during preg-
nancy seen in the Routine iron group. The interim birth
data suggested a longer hospital stay after birth and higher
risk of negative fetal heart beat in the Routine iron group.
However, all these differences were statistically non-
signiﬁcant and the complete birth data are needed to con-
clude any putative effects of iron on birth outcomes.
One of the strengths of our trial is its large sample. So
far, this represents the largest trial investigating the ben-
eﬁts of prophylactic iron during pregnancy on MCH in
malaria-endemic settings. The compliance of the study
nurses with the trial protocol and that of the women
with regard to uptake of the iron and folic acid tablets
was good, as was the follow-up during pregnancy.22
However, during pregnancy, we lacked objective mea-
sures of malaria; hence, our results may not reﬂect the
putative effect of iron on clinical malaria. The collection
of delivery data was challenging, resulting in up to an
estimated 40% of missing birth data. We did not realise
the extent of the problem until most deliveries had
occurred. We are currently tracing the birth data using
various methods (abstracting hospital records and death
register data and calling women), with results to be
reported separately after ﬁnalisation.
A comparison of our ﬁndings with previous studies
conducted in malaria-endemic areas is problematic
because of key differences: previous studies have com-
pared iron versus no iron, and our study compares two
policies of iron administration: routine prophylaxis
versus screening and treatment. Nevertheless, studies
from Nigeria11 and Gambia12 found no signiﬁcant effect
of iron prophylaxis on malaria; they had used a more
reliable measure of malaria (clinical and parasitological
analysis). A Ugandan study14 did not observe any effect
of iron supplementation on the incidence of congenital
malaria in the offspring. A Bangladeshi study10 found a
difference in preterm delivery (less in the non-iron
group), but no association was seen with the other out-
comes examined, similar to the Nigerian study,11 includ-
ing abortion, hypertension, eclampsia, postnatal
complications, birth weight, Apgar scores, prematurity,
development of diarrhoea at 6 weeks and perinatal mor-
tality. Other beneﬁts reported with iron prophylaxis
include increased mean birth weight,12 14 reduced inci-
dence of prematurity12 and increased birth length and
Apgar score.13
Although more complete birth data are needed to
reach ﬁrm conclusions, we can speculate that the poten-
tial for a higher incidence of unavailable delivery data in
the Routine iron group may indicate that these women
had more adverse outcomes, such as miscarriage and
stillbirths, and consequently did not deliver in the
expected health centres. Similarly, the higher likelihood
of longer mother’s hospital stay after birth in the
Routine iron group may also be indicative of more pro-
blems at birth. Delivery by caesarean section did not
explain the longer hospital stay as the estimate remained
the same after excluding the births that occurred by cae-
sarean section.
Anaemia has been associated with MCH risks,24–26 and
the association between iron and increased risk of infec-
tions5–7calls for more deﬁnitive evidence on the beneﬁts
of iron prophylaxis during pregnancy in settings with
increased infectious diseases where infections remain a
major cause of maternal and child mortality.8 9 Our trial
in Maputo, Mozambique is an attempt to investigate
whether routine iron prophylaxis during pregnancy
Table 4 Numbers, proportions (%) and risk ratios (RR, 95% CIs of birth outcomes by iron groups
Outcomes
Selective
iron n
Routine
iron n
Selective
iron (%)
Routine
iron (%)
Selective
iron
Routine iron RR
(95% CI)† p Value
Primary health outcomes
Low birth weight (<2500 g) 136 142 11.8 12.8 1.00 1.09 (0.88 to 1.36) 0.431
Preterm delivery (<37 weeks) 331 299 28.8 27.0 1.00 0.96 (0.84 to1.09) 0.185
Secondary health outcomes
Caesarean section delivery 15 22 1.3 2.0 1.00 1.48 (0.77 to 2.84) 0.238
Negative fetal heart beat at
admission
18 29 1.6 2.6 1.00 1.66 (0.93 to 2.96) 0.089
Child ill or dead at birth 29 33 2.5 3.0 1.00 1.20 (0.73 to 1.96) 0.473
Mother ill or dead at birth 5 6 0.4 0.5 1.00 1.25 (0.38 to 4.09) 0.711
Other outcomes
Delivery in reference centre* 210 185 18.3 16.7 1.00 0.91 (0.76 to 1.09) 0.316
Long hospital stay after delivery
(≥ 3 days)
46 62 4.0 5.6 1.00 1.43 (0.97 to 1.26) 0.059
No delivery data 993 1075 46.4 49.2 1.00 1.06 (1.00 to 1.13) 0.060
*Jose Macamo or Mavalane or Central Hospital.
†The estimates were not adjusted for any baseline characteristic because the two groups did not differ from each other at baseline.
8 Parkkali S, Abacassamo F, Nwaru BI, et al. BMJ Open 2013;3:e001948. doi:10.1136/bmjopen-2012-001948
Prenatal iron prophylaxis and maternal and child health
is more effective than screening and treatment for
anaemia in improving MCH in an area of endemic
malaria and HIV.
CONCLUSIONS
These interim results from this pragmatic RCT indicate
that routine iron prophylaxis during pregnancy did not
suggest better MCH outcomes than the policy of screening
and treatment for anaemia. If anything, screening and
treatment for anaemia appeared to be better. Complete
birth data are needed for a ﬁrm conclusion. Which of the
two methods, Routine or Selective iron prophylaxis, is
more feasible will be discussed in later publications.
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